Article info
PDFShort report
Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis
- Correspondence to Belén Rodríguez de Castro, Hospital Universitario Cabueñes, Gijón 33394, Spain; b.rocas23{at}gmail.com
Citation
Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis
Publication history
- Received July 25, 2019
- Revised October 2, 2019
- Accepted October 7, 2019
- First published October 16, 2019.
Online issue publication
January 09, 2022
Article Versions
- Previous version (20 February 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ.